SCHEMBL15913993

SCHEMBL15913993

O=C1c2ccccc2C(=O)N1[C@H]1C=C(c2ccncc2[N+](=O)[O-])CC[C@@H]1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 3/20 0.37
CRBN Q96SW2 3/20 0.37
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 5/20 0.34
MAPT P10636 2/20 0.33
HTT P42858 3/20 0.32
RAB9A P51151 2/20 0.32
POLB P06746 1/20 0.32
MAPK1 P28482 1/20 0.32
CCR6 P51684 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CYP1A2 P05177 1/20 0.31
GRM5 P41594 1/20 0.31
CHRM2 P08172 1/20 0.31
OPRM1 P35372 1/20 0.31
IKZF3 Q9UKT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15913994 1.00 DDB1 (0.37) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL13833230 1.00 DDB1 (0.37) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL1723265 0.83 CYP1A2 (0.43) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL13734994 0.78 KMT2A (0.40) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL15913592 0.77 CYP1A2 (0.32) DDB1CRBNALDH1A1TDP1CYP1A2
SCHEMBL15913596 0.77 CYP1A2 (0.32) DDB1CRBNALDH1A1TDP1CYP1A2
SCHEMBL15913597 0.77 CYP1A2 (0.32) DDB1CRBNALDH1A1TDP1CYP1A2
SCHEMBL13833259 0.77 CYP1A2 (0.32) DDB1CRBNALDH1A1TDP1CYP1A2
SCHEMBL1711337 0.73 KDM4E (0.34) DDB1CRBNMEN1KMT2AKDM4E
SCHEMBL13734631 0.72 MEN1 (0.40) MEN1KMT2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187486-B2 Bicyclic pyridazine compounds as Pim inhibitors AMGEN INC. (US) 2015-11-17 US disclosed
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors AMGEN INC. 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221344-A1 Bicyclic Pyridazine Compounds as PIM Inhibitors PIM1, PIM2, PIM3 DDB1 1737/4885CRBN 749/4885MEN1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.